Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 patients with up to three metastatic lesions, randomized into two arms. Results show improved biochemical and clinical progression-free survival in the combination arm. Dr. Marvaso highlights that patients with favorable characteristics, such as low PSA levels and longer time from initial treatment, may still benefit from SBRT alone. The study observes that most relapses in the combination arm were oligo-recurrences. Future analyses will include quality of life assessments and molecular analysis of biological samples. Dr. Marvaso emphasizes the importance of patient selection in treatment decisions, suggesting that while the combination therapy appears superior, SBRT alone may be appropriate for carefully selected patients.

Biographies:

Giulia Marvaso, MD, Radiation Oncologist, European Institute of Oncology Milan, Assistant Professor, Department of Oncology, The University of Milan, Milan, Italy

Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Well Star MCG, Georgia Cancer Center, Augusta, GA